Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) and Sigyn Therapeutics (OTCMKTS:SIGY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Earnings and Valuation
This table compares Ironwood Pharmaceuticals and Sigyn Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ironwood Pharmaceuticals | $308.52 million | 1.01 | $880,000.00 | ($0.05) | -38.50 |
| Sigyn Therapeutics | N/A | N/A | -$3.34 million | ($4.77) | -0.42 |
Insider & Institutional Ownership
10.0% of Sigyn Therapeutics shares are owned by institutional investors. 12.7% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 78.5% of Sigyn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Ironwood Pharmaceuticals and Sigyn Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ironwood Pharmaceuticals | -2.25% | -2.46% | 2.19% |
| Sigyn Therapeutics | N/A | N/A | -2,842.57% |
Analyst Ratings
This is a summary of recent recommendations for Ironwood Pharmaceuticals and Sigyn Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ironwood Pharmaceuticals | 1 | 6 | 1 | 0 | 2.00 |
| Sigyn Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Ironwood Pharmaceuticals currently has a consensus price target of $4.94, suggesting a potential upside of 156.62%. Given Ironwood Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Sigyn Therapeutics.
Risk and Volatility
Ironwood Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Sigyn Therapeutics has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500.
Summary
Ironwood Pharmaceuticals beats Sigyn Therapeutics on 8 of the 13 factors compared between the two stocks.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
About Sigyn Therapeutics
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
